Alexander C. Razavi MD, PhD, MPH , Aaron L. Troy MD, MPH , Jaideep Patel MD , Laxmi S. Mehta MD , Jared A. Spitz MD , Donald Lloyd-Jones MD, ScM , Seamus P. Whelton MD, MPH , Michelle C. Johansen MD, PhD , Roger S. Blumenthal MD
{"title":"Future of Stroke Prevention","authors":"Alexander C. Razavi MD, PhD, MPH , Aaron L. Troy MD, MPH , Jaideep Patel MD , Laxmi S. Mehta MD , Jared A. Spitz MD , Donald Lloyd-Jones MD, ScM , Seamus P. Whelton MD, MPH , Michelle C. Johansen MD, PhD , Roger S. Blumenthal MD","doi":"10.1016/j.jacadv.2025.101724","DOIUrl":null,"url":null,"abstract":"<div><div>Approximately 9 to 10 million adults (4%) have experienced a stroke in the United States. While stroke incidence has generally declined, progress has been less pronounced among young individuals, and such trends have underlined the importance of focusing on the primary prevention of stroke. In 2024, the American Heart Association and American Stroke Association released new guidelines for the primary prevention of stroke. Here, we review major updates in 7 domains: dietary modification, glucagon-like peptide-1 receptor agonists, blood pressure targets, lipid-lowering medications, antithrombotic agents, colchicine therapy, and sex-specific preventive risk assessment. Through this process, we review important randomized controlled trial evidence contributing to guideline updates and provide key perspectives on the incorporation of lifestyle and pharmacotherapy for personalized stroke prevention.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 6","pages":"Article 101724"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772963X25001413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Approximately 9 to 10 million adults (4%) have experienced a stroke in the United States. While stroke incidence has generally declined, progress has been less pronounced among young individuals, and such trends have underlined the importance of focusing on the primary prevention of stroke. In 2024, the American Heart Association and American Stroke Association released new guidelines for the primary prevention of stroke. Here, we review major updates in 7 domains: dietary modification, glucagon-like peptide-1 receptor agonists, blood pressure targets, lipid-lowering medications, antithrombotic agents, colchicine therapy, and sex-specific preventive risk assessment. Through this process, we review important randomized controlled trial evidence contributing to guideline updates and provide key perspectives on the incorporation of lifestyle and pharmacotherapy for personalized stroke prevention.